These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 24659339)
21. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer. Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378 [TBL] [Abstract][Full Text] [Related]
22. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations. Bleau AM; Freire J; Pajares MJ; Zudaire I; Anton I; Nistal-Villán E; Redrado M; Zandueta CN; Garmendia I; Ajona D; Blanco D; Pio R; Lecanda F; Calvo A; Montuenga LM Int J Cancer; 2014 Dec; 135(11):2516-27. PubMed ID: 24473991 [TBL] [Abstract][Full Text] [Related]
23. Nootkatone, an AMPK activator derived from grapefruit, inhibits KRAS downstream pathway and sensitizes non-small-cell lung cancer A549 cells to adriamycin. Hung LVM; Moon JY; Ryu JY; Cho SK Phytomedicine; 2019 Oct; 63():153000. PubMed ID: 31280139 [TBL] [Abstract][Full Text] [Related]
24. Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Ji L; Nishizaki M; Gao B; Burbee D; Kondo M; Kamibayashi C; Xu K; Yen N; Atkinson EN; Fang B; Lerman MI; Roth JA; Minna JD Cancer Res; 2002 May; 62(9):2715-20. PubMed ID: 11980673 [TBL] [Abstract][Full Text] [Related]
25. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Lin J; Sun T; Ji L; Deng W; Roth J; Minna J; Arlinghaus R Oncogene; 2007 Oct; 26(49):6989-96. PubMed ID: 17486070 [TBL] [Abstract][Full Text] [Related]
26. Suppression of lung cancer cell invasion by LKB1 is due to the downregulation of tissue factor and vascular endothelial growth factor, partly dependent on SP1. Liang X; Li ZL; Jiang LL; Guo QQ; Liu MJ; Nan KJ Int J Oncol; 2014 Jun; 44(6):1989-97. PubMed ID: 24647869 [TBL] [Abstract][Full Text] [Related]
27. Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer. Yang R; Li SW; Chen Z; Zhou X; Ni W; Fu DA; Lu J; Kaye FJ; Wu L J Natl Cancer Inst; 2019 Jul; 111(7):664-674. PubMed ID: 30423141 [TBL] [Abstract][Full Text] [Related]
28. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167 [TBL] [Abstract][Full Text] [Related]
29. LKB1 promotes cell survival by modulating TIF-IA-mediated pre-ribosomal RNA synthesis under uridine downregulated conditions. Liu F; Jin R; Liu X; Huang H; Wilkinson SC; Zhong D; Khuri FR; Fu H; Marcus A; He Y; Zhou W Oncotarget; 2016 Jan; 7(3):2519-31. PubMed ID: 26506235 [TBL] [Abstract][Full Text] [Related]
30. Enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) by adenovirus-mediated ING4 gene therapy. Ling C; Xie Y; Zhao D; Zhu Y; Xiang J; Yang J Cancer Gene Ther; 2012 Oct; 19(10):697-706. PubMed ID: 22863759 [TBL] [Abstract][Full Text] [Related]
31. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915 [TBL] [Abstract][Full Text] [Related]
32. The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis. Shao C; Zhao L; Wang K; Xu W; Zhang J; Yang B World J Surg Oncol; 2012 Aug; 10():160. PubMed ID: 22866867 [TBL] [Abstract][Full Text] [Related]
34. Induction of tumor inhibition and apoptosis by a candidate tumor suppressor gene DRR1 on 3p21.1. Liu Q; Zhao XY; Bai RZ; Liang SF; Nie CL; Yuan Z; Wang CT; Wu Y; Chen LJ; Wei YQ Oncol Rep; 2009 Nov; 22(5):1069-75. PubMed ID: 19787223 [TBL] [Abstract][Full Text] [Related]
35. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer. Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711 [No Abstract] [Full Text] [Related]
36. MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer. Wu X; Liu T; Fang O; Dong W; Zhang F; Leach L; Hu X; Luo Z Oncotarget; 2016 Jan; 7(3):2417-32. PubMed ID: 26678031 [TBL] [Abstract][Full Text] [Related]
37. Myristoylation of the fus1 protein is required for tumor suppression in human lung cancer cells. Uno F; Sasaki J; Nishizaki M; Carboni G; Xu K; Atkinson EN; Kondo M; Minna JD; Roth JA; Ji L Cancer Res; 2004 May; 64(9):2969-76. PubMed ID: 15126327 [TBL] [Abstract][Full Text] [Related]
38. The AMPK-Related Kinases SIK1 and SIK3 Mediate Key Tumor-Suppressive Effects of LKB1 in NSCLC. Hollstein PE; Eichner LJ; Brun SN; Kamireddy A; Svensson RU; Vera LI; Ross DS; Rymoff TJ; Hutchins A; Galvez HM; Williams AE; Shokhirev MN; Screaton RA; Berdeaux R; Shaw RJ Cancer Discov; 2019 Nov; 9(11):1606-1627. PubMed ID: 31350328 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of RBM5 induces autophagy in human lung adenocarcinoma cells. Su Z; Wang K; Li R; Yin J; Hao Y; Lv X; Li J; Zhao L; Du Y; Li P; Zhang J World J Surg Oncol; 2016 Feb; 14():57. PubMed ID: 26923134 [TBL] [Abstract][Full Text] [Related]
40. Metformin and tenovin-6 synergistically induces apoptosis through LKB1-independent SIRT1 down-regulation in non-small cell lung cancer cells. Lee BB; Kim Y; Kim D; Cho EY; Han J; Kim HK; Shim YM; Kim DH J Cell Mol Med; 2019 Apr; 23(4):2872-2889. PubMed ID: 30710424 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]